Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul 2;14(7):13748–13762. doi: 10.3390/ijms140713748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the authors; licensee MDPI, Basel, Switzerland

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

Western blot analysis. (A) Western blot analysis showed a higher level of p-ERK protein expression in MDAH2774 cells than in other cell lines; (B) Dual-color fluorescence in situ hybridization (FISH) validated amplification of the KRAS gene in ovarian cancer cell line (MDAH2774) White arrows indicate amplification of KRAS gene; (C) OVCAR3 cells contained signals for both KRAS and reference probes with an approximate 1:1 ratio; (D) Western blot analysis showed a significant reduction in p-ERK protein in PD0328901-treated cells compared with control DMSO-treated cells; (E) IC₅₀ values for the selective MEK1/2 inhibitor PD0325901 for 6 type II ovarian carcinoma cell lines. MDAH2774 cells with KRAS amplification were more sensitive to growth inhibition by the selective MEK1/2 inhibitor PD0325901 than cells without KRAS amplification. The mean and SD were obtained from 3 experiments.

Western blot analysis. (A) Western blot analysis showed a higher level of p-ERK protein expression in MDAH2774 cells than in other cell lines; (B) Dual-color fluorescence in situ hybridization (FISH) validated amplification of the KRAS gene in ovarian cancer cell line (MDAH2774) White arrows indicate amplification of KRAS gene; (C) OVCAR3 cells contained signals for both KRAS and reference probes with an approximate 1:1 ratio; (D) Western blot analysis showed a significant reduction in p-ERK protein in PD0328901-treated cells compared with control DMSO-treated cells; (E) IC₅₀ values for the selective MEK1/2 inhibitor PD0325901 for 6 type II ovarian carcinoma cell lines. MDAH2774 cells with KRAS amplification were more sensitive to growth inhibition by the selective MEK1/2 inhibitor PD0325901 than cells without KRAS amplification. The mean and SD were obtained from 3 experiments.